{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=6",
    "query": {
      "intervention": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 177,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T17:44:37.903Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07702461",
      "title": "Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity & Overweight",
        "Diabetes (DM)"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-06-12",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07702461"
    },
    {
      "nct_id": "NCT03249506",
      "title": "Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase-4 Inhibitor (DPP-4)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinedione (TZD)",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylureas",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25358,
      "start_date": "2016-05-12",
      "completion_date": "2017-11-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-21",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Trevose, Pennsylvania",
      "locations": [
        {
          "city": "Trevose",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03249506"
    },
    {
      "nct_id": "NCT07140289",
      "title": "Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastric Emptying",
        "Glucagon-Like Peptide-1 Receptor Agonists",
        "Intermittent Fasting",
        "Intraoperative Complication Due to Anesthesia",
        "Respiratory Aspiration of Gastric Contents"
      ],
      "interventions": [
        {
          "name": "Ultrasound of gastric contents",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Wael Saasouh, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-09-01",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07140289"
    },
    {
      "nct_id": "NCT07760948",
      "title": "HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)",
        "Sarcopenia",
        "Obesity",
        "Muscle Loss",
        "Older Adults"
      ],
      "interventions": [
        {
          "name": "Calcium-HMB Plus Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Matching placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-12-01",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07760948"
    },
    {
      "nct_id": "NCT04019197",
      "title": "Effects of Semaglutide in HIV-Associated Lipohypertrophy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "Lipohypertrophy",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Western Reserve University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2019-05-16",
      "completion_date": "2026-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Charleston, South Carolina",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019197"
    },
    {
      "nct_id": "NCT06069622",
      "title": "Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "24-hour ambulatory blood pressure",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Liberal salt diet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-11-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06069622"
    },
    {
      "nct_id": "NCT07740291",
      "title": "Tirzepatide Impact Assessment Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity & Overweight",
        "Cardiometabolic Health Indicators",
        "Addiction",
        "Eating Disorders",
        "Mental Health"
      ],
      "interventions": [
        {
          "name": "GLP-1 Receptor Agonist Therapy",
          "type": "DRUG"
        },
        {
          "name": "Structured Lifestyle Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-01-02",
      "completion_date": "2026-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07740291"
    },
    {
      "nct_id": "NCT04034524",
      "title": "Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2019-05-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04034524"
    },
    {
      "nct_id": "NCT04039503",
      "title": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 475,
      "start_date": "2019-08-30",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 5,
      "location_summary": "Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Nashua",
          "state": "New Hampshire"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Norman",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04039503"
    },
    {
      "nct_id": "NCT07227948",
      "title": "Repurposing Semaglutide for the Treatment of Cocaine Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "cognitive behavioral therapy (CBT).",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2026-01-15",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-14T17:44:37.903Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227948"
    }
  ]
}